Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBIT Margin (2022 - 2026)

bioAffinity Technologies has reported EBIT Margin over the past 5 years, most recently at 267.62% for Q1 2026.

  • Quarterly EBIT Margin fell 12589.0% to 267.62% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 204.29% through Mar 2026, down 9491.0% year-over-year, with the annual reading at 171.58% for FY2025, 7594.0% down from the prior year.
  • EBIT Margin was 267.62% for Q1 2026 at bioAffinity Technologies, down from 196.94% in the prior quarter.
  • Over five years, EBIT Margin peaked at 80.84% in Q1 2024 and troughed at 169160.69% in Q1 2023.
  • The 5-year median for EBIT Margin is 197.55% (2025), against an average of 24179.53%.
  • Year-over-year, EBIT Margin soared 16907986bps in 2024 and then crashed -12589bps in 2026.
  • A 5-year view of EBIT Margin shows it stood at 69213.17% in 2022, then soared by 100bps to 105.83% in 2023, then fell by -26bps to 133.47% in 2024, then plummeted by -48bps to 196.94% in 2025, then tumbled by -36bps to 267.62% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's EBIT Margin are 267.62% (Q1 2026), 196.94% (Q4 2025), and 158.56% (Q3 2025).